CBA-1535 + pembrolizumab

CBA-1535 + pembrolizumab is a combination investigational therapy under clinical development for advanced solid tumors and refractory cancers. CBA-1535 is a humanized multi-specific antibody classified as a tribody, with two binding sites targeting the 5T4 protein (expressed in various solid tumors) and one site targeting CD3 on T cells, designed to facilitate T cell engagement and activation against tumor cells. Pembrolizumab is a programmed death-1 (PD-1) immune checkpoint inhibitor (marketed as Keytruda), which enhances T-cell mediated immune responses against tumors by blocking the PD-1 pathway. The combination is being evaluated to potentiate antitumor immune response through both active T cell engagement (by CBA-1535) and checkpoint blockade (by pembrolizumab). Both drugs are administered intravenously: CBA-1535 is given weekly, while pembrolizumab is dosed every three weeks. The combination is under clinical investigation in Japan, with Phase 1 trials underway to assess safety, tolerability, pharmacokinetics, biomarkers, and preliminary efficacy in patients with advanced solid tumors and refractory cancer[1][2][3][4][5][6][7][9][10].

Other names

CBA-1535 + pembrolizumab